1. Scrip
  2. >>Business

With 2023's Largest Indian IPO, Mankind Listing Watched; GPCR-Based Candidate Enters Trials

Transplant, Oncology Divisions Planned

 
• By Vibha Ravi

Scrip takes a look at what a listing of Mankind Pharma, which has thrice the revenues of Pfizer’s India unit and the fourth largest domestic pharma sales, would mean. A GPCR-based candidate against type-2 diabetes and obesity is in Phase I trials and a search on India’s trial registry reveals a study for an ayurvedic preparation against diabetes

IPO Concept
Mankind's IPO Is Indian Pharma's Biggest In 2023 So Far • Source: Shutterstock

It’s not every day that a company the size of Mankind Pharma Ltd. makes a debut on Indian stock markets. With three times the operational revenue of Pfizer’s India unit, the fourth largest Indian pharmaceutical company by domestic sales is set to list on Indian stock exchanges on 8 May.

The last time a comparable pharma firm made an initial public offering (IPO) was nearly two and a half years...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

More from Scrip

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.